GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Total Equity

AXDX (Accelerate Diagnostics) Total Equity : $-48.48 Mil (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Total Equity?

Accelerate Diagnostics's total equity for the quarter that ended in Sep. 2024 was $-48.48 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Accelerate Diagnostics Total Equity Historical Data

The historical data trend for Accelerate Diagnostics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Total Equity Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.38 -62.81 -35.07 -22.26 -19.89

Accelerate Diagnostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.03 -19.89 -25.78 -34.89 -48.48

Accelerate Diagnostics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Accelerate Diagnostics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=31.366-51.254
=-19.89

Accelerate Diagnostics's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=32.315-80.796
=-48.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Total Equity Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Total Equity
Comparable Companies
ICAD ICCM XAIR DHAI OM COCH ADGM RDGL BSGM TRIB ABT SYK BSX MDT XTER:SHL SZSE:300760 EW DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
0H8E:UK 1A80:Germany
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Website
https://www.acceleratediagnostics.com
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Executives
John Patience director, 10 percent owner 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry Michael Mertz officer: Chief Technology Officer 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Jack Phillips director, officer: PRESIDENT AND CEO 11731 YALE DR, CARMEL IN 46032
David Patience officer: Chief Financial Officer C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Marran H. Ogilvie director 599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan director C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black director 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling officer: CFO 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price officer: SVP & HEAD OF COM OPS AMERICAS 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris director 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Mark C Miller director C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Louise Francesconi director 870 WINTER STREET, WALTHAM MA 02451
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714